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4) (a) 
ABSTRACT 
Background 
Penemuan Projek/Abstrak 
(Perfu disediakan makluman di antara 100 - 200 perkataan di dalam Bahasa Malaysia dan Bahasa 
lnggeris. lni kemudiannya akan dimuatkan ke dalam Laporan Tahunan Sahagian Penyefidikan & 
Pembangunan sebagai satu cara untuk menyampaikan dapatan projek tuanfpu~n kepada pihak 
Universiti). 
(English version) 
Nasopharyngeal carcinoma (NPC) is common in Malaysia but diagnosis is sometimes delayed for 
non-representative biopsy, submucosal disease and occult primaries- increasing m·arbidity and 
mortality. Epstein-Barr virus (EBV) is associated with all types of NPC and DNA in tumor cells is 
detectable by polymerase chain reaction (PCR). EBV products EBNA 1, EBNA2 and LMP1 are 
implicated in oncogenesis and is detectable in nodal tissue. However no similar study has been 
done in Southeast-Asia with adequate sample. 
Objectives 
This study evaluates the validity and reliability of detecting EBV genes in biopsy and FNAC tissue 
in NPC by PCR. 
Methodology 
Tissue from 72 nasopharyngeal biopsies were collected from consented patients. 36 were 
positive and 36 negatives served as controls. Tissue from 70 fine-needle aspirations were 
similarly obtained. 35 belonged to NPC-positive patients, and 35 of other pathologies served as 
controls. 
DNA was extracted, amplified with forward and reverse primers for EBNA 1, EBNA2, LMP1 genes 
and human a-actin gene as control, and detected by electrophoresis. Cloned DNA from 895-8 
cell line served as positive control. 
Histopathological-proven primary tumour and clinico-pathological criteria for neck nodes (clinically 
suspicious neck node with histopathologically-confirmed primary tumour) were used as gold 
standard. 
Results 
35/36 positive nasopharyngeal biopsies and 35/36 negatives contained sufficient DNA. EBNA 1 
gene was detected in 34/35 positive specimens but were undetected in the controls. EBNA2 gene 
was detected in 31/35 positive specimens and in 2/35 controls. LMP1 was detected in 32/35 
positive specimens and in 4/35 controls. (P > 0.05 by McNemar_s test-- i.e. no significant 
difference from histopathology.) EBNA1 has the best sensitivity (97.1%) and specificity (100%) 
(Kappa = 0.97). One patient in the control group was positive for EBV DNA and developed NPC 
1 year later. Another patient with obvious nasopharyngeal tumour was negative on the 1st biopsy 
and confirmed on repeat biopsy 2 weeks later, but EBV DNA was detected in ~oth specimens. 
35/36 metastatic NPC specimens contained sufficient DNA and one was excluded due to 
presence of second primary. EBNA 1 gene was detected in 30/34 nodes and 1/34 rontro1s. 
EBNA2 gene was detected in 29/34 nodes and none of the controls. LMP1 gene was detected in 
30/34 nodes and in 2134 of controls. (P > 0.05 by McNemar_s test_ i.e. no significant difference 
from clinico-pathological criteria for neck metastasis). A cut-off point of >0/3 genes offers the 
highest sensitivity (97.1%} and specificity (94.1%) (Kappa= 0.91 ). 
All histological types of NPC contained EBV DNA. 
Conclusion 
EBV DNA detection is reliable and a~rate in di~gnosing NPC. On par with histopathology in 
detecting primary tumours, it ~lso predtcts.the dev~l?pment ?f NPC. On par with clinico-
pathological criteria in detecting metastatic NPC, 1t IS supenor to fine-needle cytology and can 
suggest NPC in occult primaries. 
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Latarbelakang 
ABSTRACT 
(Bahasa Melayu version) 
Karsinoma nasofaring (NPC) adalah kerap di Malaysia tetapi diagnosanya seringkali tertunda-
disebabkan biopsi yang tidak tepat, pen yak it submukosa, dan _occult primary __ menyebabkan 
morbiditi dan mortality meningkat. Virus Epstein-Barr (EBV) adalah berkait dengan semua janis 
NPC dan DNA dalam sel-sel kanser boleh dikesan dengan tindakbalas rantai polymerase (PCR). 
Hasil-hasil EBV EBNA 1, EBNA2 dan LMP1 telah diimplikasikan dalam onkogenesi~ dan boleh 
dikesan dalam tisu noda limfa. Walaubagaimanapun tiada kajian yang serupa pemah dijalankan 
di Asia Tenggara dengan saiz contoh yang memadai. 
Objektif 
Kajian ini menilaikan kejituan dan keberkesanan pengesanan gen EBV dalam tisu biopsi dan 
FNAC dalam NPC. 
Kaedah 
Tisu dari 72 biopsi nasofaring tefah diambil dari pesakit-pesakit yang memberi keizinan. 
Antaranya 36 positif dan 36 negatif dijadikan kawalan. Tisu dari 70 aspirasi-jarum·halus diambil 
juga. Antaranya 35 diambil dari pesakit NPC dan 35 dari penyakit lain yang dijadikan kawalan. 
DNA telah diekstrak, diamplifikasi dengan primer hadapan dan belakang bagi gen-gen EBNA 1, 
EBNA2, LMP1 dan juga gen a-actin manusia sebagai kawalan, dan dikesan dengan 
elektroforesis. DNA yang diklon dari kultur sel 895-8 dijadikan kawalan positif. 
Keputusan 
35/36 biopsi nasofaring positif dan 35/36 negatif mengandungi DNA yang mencukupi. Gen 
EBNA 1 telah dikesan dalam 34/35 spesimen positif dan tiada dikesan dalam spesimen kawalan. 
Gen EBNA2 dikesan dalam 31/35 spesimen positif dan dalam 2/35 kawalan. lMP1 dikesan 
dalam 32/35 spesimen positif dan 4135 kawalan. (Nilai P > 0.05 dengan ujian McNemar_s _ 
menunjukkan tiada perbezaan ketara disbanding dengan histopatologi.) EBNA 1 menunjukkan 
sensitiviti (97.1 %) dan spesifisiti (1 00%) yang terbaik (Kappa = 0.97). Seorang pesakit dalam 
kumpulan kawalan yang EBV DNA positif telah mendapat NPC 6 dalam masa 1 tahun kemudian. 
Seorang pesakit lagi mempunyai ketumbuhan ketara dalam nasofaring tetapi biopsi pertamanya 
negatif manakala biopsi 2 minggu kemudian positif, tetapi DNA EBV telah dikesan dalam kedua-
dua specimen. 
35/36 spesimen NPC metastatik mengandungi DNA yang mencukupi dan satu diketepikan akibat 
ketumbuhan kedua. Gen EBNA 1 dikesan dalam 30134 noda dan 1/34 .kawalan. Gen EBNA2 
dikesan dafam 29/34 noda dan tiada dalam kawalan. Gen lMP1 dikesan dalam 30/34 noda dan 
2/34 kawalan. (P > 0.05 dengan ujian McNemar_ iaitu tiada perbezaan ketara disbanding 
dengan kriteria kliniko-patologi.) Nilai _cut-off_ >0/3 gen memberi sensitivity (97.1%) dan 
spesifisiti (94.1%) yang terbaik (Kappa = 0.91 ). · 
Kesemua jenis NPC mengandungi DNA EBV. 
Kesimpulan 
Pengesanan DNA EBV adalah jit~ dan berkesan d~lam. men~iagnosa NPC. Ia adalah setara 
dengan histopatologi dalam pengesanan kanser pnman dan Juga boleh menjangka terjadinya 
NPC. Setara dengan kriteria kliniko·patologi dalam mengesan NPC metastatic, ia lebih baik 
daripada sitologi jarum-halus dan boleh mencadamgkan NPC dalam keadaan occult primary. 
(b) Senaraikan Kata Kunci yang digunakan di dalam abstralc 
Bahasa Malaysia Bahasa lnggeris 
Karsrnoma nasofaring Nasopharyngeal Carcinoma 
Ekstraksi DNA DNA extraction 
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(b) Faedah-Faedah Lain Seperti Perkembangan Produk, Prospek Komersialisasi 
Dan Pendaftaran Paten. .. 
(Jika ada dan jika perlu, sila guna kertas berasingan) 
i. Based on this research is a quick diagnostic kit called Ez EBV Amp- A DNA-
based diagnostic kit for the detection of Epstein-Barr virus in l 
Nasopharyngeal Carcinoma. This kit is being patented. This is an· innovation 
which has been received with surprised by all the participants of Asia-Oceania 
Congress and many of them have contacted us and shown their interest to use 
this kit in cases with problems of diagnosis. We intented to present this kit in a 
number of future conferences once the kit is commercially available. 
ii. Kit has been used in Hospital USM in difficult cases of diagnosis with 
encouraging result. 
iii. Ez EBV Amp- A DNA-based diagnostic kit has bwon the number of awards 
including the Gold medal at national and international level 
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Diagnosis of Nasopharyngeal Carcinoma by DNA Amplification of 
EBV Genomes in Nasopharyngeal Biopsy and F.ine-Needle · 
Aspiration of Neck Nodes 
Shahid Hassan, Yap Y.Y, Ravichandran M. 
Abstract 
Background 
Nasopharyngeal carcinoma (NPC) is common in Malaysia but diagnosis is sometimes delayed for non-
representative biopsy, submucosal disease and occult primaries - increasing morbidity and mortality. Epstein-
Barr virus (EBV) is associated with all types ofNPC and DNA in tumor cells is detectable by polymerase chain 
reaction (PCR). EBV products EBNA1, EBNA2 and LMPl are implicated in oncogenesis and is detectable in 
nodal tissue. However no similar study has been done in Southeast-Asia with adequate sample. 
Objectives 
This study evaluates the validity and reliability of detecting EBV genes in biopsy and FNAC tissue in NPC by 
PCR 
Methodology 
Tissue from 72 nasopharyngeal biopsies were collected from consented patients. 36 were positive and 36 
negatives served as controls. Tissue from 70 fine-needle aspirations were similarly obtained. 35 belonged to 
NPC-positive patients, and 35 of other pathologies served as controls. 
DNA was extracted, amplified with forward and reverse primers for EBNA1, EBNA2, LMPI genes and human 
P-actin gene as control, and detected by electrophoresis. Cloned DNA from B95-8 cell line served as positive 
control. 
Histopathological-proven primaly tumour and clinico-pathological criteria for neck nodes (clinically suspicious 
neck node with histopathologically-confirmed primary tmnour) were used as gold standard. 
Results 
35/36 positive nasopharyngeal biopsies and 35/36 negatives contained sufficient DNA EBNAI gene was 
detected in 34/35 positive specimens but were undetected in the controls. EBNA2 gene was detected in 31/35 
positive specimens and in 2/35 controls. LMPI was detected in 32/35 positive specimens and in 4/35.controls. 
(P > 0.05 by McNemar's test-- i.e. no significant difference from histopathology.) E:BNAl has the best 
sensitivity (97 .1 %) and specificity ( 1 00%) (Kappa= 0~ 97). One patient in the control group was positive for 
EBV DNA and developed NPC 1 year later. Another patient with obvious nasopharyngeal tumour was negative 
on the 1st biopsy and confirmed on repeat biopsy 2 weeks later, but EBV DNA was detected in both specimens. 
35/36 metastatic NPC specimens contained sufficient DNA and one was excluded due to presence of second 
primary. EBNA1 gene was detected in 30/34 nodes and 1/34 controls. EBNA2 gene was detected in 29/34 
nodes and none of the controls. LMPl gene was detected in 30/34 nodes and in 2/34 of controls. (P ::> 0.05 by 
McNemar's test- i.e. no significant difference from clinico-pathological criteria for neck metastasis). A cut-off 
point of >0/3 genes offers the highest sensitivity (97.1 %) and specificity (94.1 %) (Kappa= 0.91). 
All histological types ofNPC contained EBV DNA. 
Conclusion 
EBV DNA detection is reliable and accurate in diagnosing NPC. On par with histopathology in detecting 
primary twnours, it also predicts the development ofNPC. On par with clinico-pathological criteria in detecting 
metastatic NPC, it is superior to fine-needle cytology and can suggest NPC in occult primaries. 
' 
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1 Introduction 
1.1 
1.1.1 
1.1.2 
Nasopharyngeal carcinoma (NPC) is a potentially curable disease if detected· early. 
However, many pitfalls in the detection ofNPC may delay diagnosis, increase morbidity 
and mortality, and worsen the prognosis of the disease. These include late presentation, 
late referral to the ENT surgeon, difficulties in interpreting biopsy material and the entity 
of the 'occult primary'. This study evaluates DNA amplification by polymerase chain 
reaction (PCR) of Epstein-Barr virus (EBV) genes and its role in areas of dilemma in the 
diagnosis ofNPC. I 
Background 
Carcinoma of the nasopharynx 
Nasopharyngeal carcinoma (NPC) is an epithelial twnour that is rare in most parts of the 
world - the incidence rate being less than I per 100,000 persons per year. It has a distinct 
geographical and population pattern, gravitating towards China, Southeast Asia, Africa, 
Canada, Alaska and Greenland Eskimos. The highest incidence is observed in the 
Cantonese-speaking Chinese of Guangdong province in South China, with an incidence 
of 30-50 per 100,000 persons per year, and high frequencies are observed similarly in 
emigrant southern Chinese populations in South-east Asia 
NPC is the commonest head and neck cancer in Malaysia In Peninsular Malaysia, the 
incidence of NPC is 365 cases per year or 5.4 per 100,000 population (Prasad and 
Rampal, 1992). This disease affects mostly the Chinese (14.6 per 100,000), followed by 
the Malays (1.3 per 100,000) and least of all, the Indians (0.5 per 100,000). The highest 
incidences fall in the states of Selangor (26.9 per 100,000), Pahang (12.3 per 100,000) 
and the Federal Territory (10.7 per 100,000). The incidence rate rises after the age of 20 
and plateaus at 40 to 59 years without any further rise with increasing age. The age-
adjusted male:female ratio is 2.8 to 1. 
NPC constitutes 85% of malignant tumours of the nasoph~ followed by lymphomas 
and other rare tumours such as the adenocarcinoma, adenoid cystic carcinoma and 
malignant melanoma (Watkinson et al., 2000). NPCs are classified by the World Health 
Organization (WHO) into three types: 
1. Type I - Keratinising squamous cell carcinoma (SCC), seen on light 
microscopy and subdivided into well-, moderately-, and poorly-
differentiated; 
2. TypeD- Nonkeratinizing carcinoma (NK) which is undifferentiated and 
shows squamous origins only on electron microscopy · and 
immunohistochemistry; and 
3. Type ill - Undifferentiated cardnoma (UC). 
All types of NPC are now regarded as variants of the squamous cell carcinoma 
However, keratinising SCC (WHO Type I) is \Dlcommon and the well-differentiated 
subtype is extremely rare. In a study of 1800 cases ofNPC in Malaysia, (Pathmanathan et 
al., 1995) f01md 17% to be WHO type I and only 0.2% to be well-differentiated. 
Epstein-Barr virus in NPC 
The Epstein-Barr virus (EBV) is a double-stranded DNA virus of the Herpesviridae 
family, first described by Epstein eta/. in 1964. Apart from their infective illnesses, EBV 
is strongly associated with Burkitt's lymphoma, B-celllymphoma, Hodgkin's disease, T 
cell lymphomas and NPC. It may sometimes be found in lymphoepithelial carcinomas of 
the stomach, salivary gland, lung and thymus (Allen, 1999, Kanegane et al., 2002), and 
also with oral cancers in Japan (Shimakage et al., 2002) 
Old et al. first described the serological relationship between EBV and NPC in 1966 and 
it has been subsequently established that patients with NPC have elevated antibody levels 
against variotis EBV -associated antigens! correlating with stage and tumour burden NPC 
cells were shown by Klein, et al. (1974) to contain multiple copies of the EBV genome. 
EBV genomes and associated antigens have consistently been found in undifferentiated 
and well-differentiated NPC (Raab-Traub et al., 1987). The strong and consistent 
association of EBV with NPC suggests that it may have an oncogenic role. 
1 
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Pathmanathan, et al. (1995) using polymerase chain reaction amplification of eDNA to 
detect EBV transcription for EBNAI, LMPI and LMP2 genes showed that all types of 
NPC, regardless of histology or differentiation, contain episomal EBV genomes and 
express specific EBV genes. Moreover EBV DNA was found in the preinvasive state of 
NPC. Similarly Huang and Lo (I 999) described the presence of EBV DNA in all forms 
ofNPC as well as the precursor state ofNasopharyngeal Intra-Epithelial Neoplasia Type 
m . 
Figure 1 • Map of the complete Epstein-Barr virus genome showing the PCR target zones for 
EBNAl, EBNA2 and LMPl genes 
2 
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1.1. 3 Polymerase Chain Reaction (PCR) 
PCR can be used to detect and amplify specific nucleic acid sequences of a virus. 
Targeted amplification of nucleic acid sequences provides dramatic increases in the 
number of copies as well as equivalent reduction in the complexity of the nucleic acid to 
be probed Also, the exponential amplification of PCR catalyzed by this biochemically 
simple cyclical process requires less than minutes per cycle obviating the need for in vitro 
cell culture of a virus which may take weeks to months. These aspects of PCR allow 
ready detection of a single virus particle especially when a specific host cell cannot be 
cultured and in latent infections where active viral replication is substantially attenuated 
thereby obviating procedures requiring the detection of proteins (Kwok and ~ninsky, 
1999). Such is the case of the Epstein-Barr virus in NPC which establishes a latent 
infection in the epithelial cells ofNPC. Needle punch biopsies and aspirates of various 
types have been shown to provide sufficient material for PCR analysis (Kwok ~d 
Sninsky, 1989). 
1.2 Problems in the diagnosis ofNPC 
1.2.1 The 'normal nasopharynx' 
A nasopharyngeal mass seen on examination can be biopsied under direct vision, utilizing 
a flexible or rigid endoscope, and the diagnosis is made quite easily. However, patients 
suspected clinically as having NPC but whose nasopharynx appears normal, will need 
deep biopsies taken from multiple sites and both Fossae ofRossenmUller. These include 
patients with persistent unilateral serous otitis media, metastatic nodal disease, raised 
EBV titres, or radiological evidence consistent with NPC. Sometimes, serial and multiple 
biopsies need to be undertaken before a diagnosis is reached (Woo, 1999). A significant 
proportion (13.3%) have occult primaries at presentation and the primary tumour may 
remain undetected even after repeated biopsies of the nasopharynx (Prasad et a/., 1983). 
Causes of false negatives are non-representative biopsies, submucosal disease, and failure 
to recognize individual malignant cells or small clumps oftumour(Allen, 1999). 
1.2.2 Cytological evaluation 
Fine-needle aspiration (FNA) of nodal disease in NPC is a useful tool and can spare the 
patient from open biopsy which worsens the long-term prognosis considerably (Cai et al., 
1983). It can make the diagnosis of metastatic undifferentiated or differentiated 
squamous carcinoma, and other carcinomas (e.g. adenocarcinoma, small cell carcinoma, 
sinonasal carcinoma). It may even suggest nasopharyngeal carcinoma as the origin when 
the presence of clusters of cohesive tumour cells, medimn-sized oval vesicular nuclei, 
prominent nucleoli, pale cytoplasm, mitotic figures and intermingling mature 
lymphocytes are seen (Chan et al., 1988). With the help of immunohistochemical 
staining, carcinomas can be differentiated from lymphomas and granulomatous diseases. 
However, FNA has limitations, which include inadequate or non-representative specimen, 
poor cellular preservation and an inexperienced cytopathologist (Chang and Chan, 1999). 
A study in Singapore on 123 fine-needle aspirates of neck masses (Kaur et al., 1993) had 
a diagnostic accuracy of 82.6% and inadequacy rate of 12.2% .. In a retrospective study 
of 57 cases of metastatic carcinoma of the neck with unknown primary found that only in 
19 cases (33.3%} could the primary site be found with a rigorous diagnostic algorithm of 
lymph node biopsy, rigid panendoscopy with systematic biopsies of suspect re~ons as 
well as blind biopsies of endoscopically inconspicuous regions, including the tongue base 
and nasopharynx and bilateral tonsillectomy (Haas et al., 2002). Chang & Chan {1999) 
proposes the detection of EBNA (Epstein-Barr virus nuclear antigen) or in-situ 
hybridisation ofEBER (Epstein-Barr virus-encoded RNA) on histological and cytological 
material as 'a very useful adjunct in diagnostic pathology', especially when conventional 
imnnmohistochemical techniques are unhelpful. 
1.3 Review of the literature 
Various studies have been done to asc~rtain the feasibility of detecting EBV DNA and 
RNA in the fine-needle aspirate of metastatic nodal disease of NPC. A comparison of 
their results is shown in the Table I below. 
Q Table 1 - Comparison of various studies done to detect EBV genes in the fine-needle 
aspirate of metastatic nodal disease in NPC 
3 
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Walter et al. 1992 USA 15/18 0/17 88.9 100 
Feinmesser et 1992 Canada 9/9 
al. 100 98.5 2/137 
Pacchioni et 1994 Italy 7/7 
al. 0/18 100 100 
MacDonald 1995 Canada 5/5 
eta/. 2/41 100 95.1 
Smith eta!. 1995 USA 111 
Akaoetal. 1996 Japan 3/3 
Lee etal. 2000 Taiwan 10/10 0/20 100 100 
These studies have all been conducted outside of Southeast Asia Their sample sizes have 
been small, ranging from 1 to 18 patients with confirmed NPC. Although they . 
demonstrate a consistently high sensitivity (88.9 - 100%) and specificity (78-100%), 
further study is needed to validate these findings with a larger sample size before PCR 
can be used as a diagnostic tool. 
In the eight studies reviewed above, two studies were done using Southern blot as the 
detection method (Ohshima et al., 1991, Smith et al., 1995) and Ohshima et al.(l991) 
found that in cancers other than the lymphoepithelioma, only PCR could reliably detect 
EBV DNA. Three other studies utilized PCR as the detection method (Feimnesser et al., 
1992b, Macdonald et al., 1995, Walter et al., 1992). In-situ hybridization on tissue 
obtained from lymph nodes were used in another three studies (Akao et al., 1996, Lee et 
al., 2000, Pacchioni ct al., 1994). 
While Lee et al. (2000) detected EBERs to indicate the presence of EBV, the other seven 
studies used EBV DNA Feinmesser et al. (1992b) used probes for EBNA1 and EBNA2 
with much success. 
In three of these studies there were patients whose primary tumour was unknown at the 
time of sampling by FNAC but neck node tissue tested positive for EBV DNA 2 out of 2 
patients in the study by Feinmesser et al. (1992b), 1 out of 2 in the study by MacDonald 
et al. (1995) and 1 out of 1 in the study by Smith et al. (1995) subsequently developed 
overt NPC which were confmned histologically. However, in none of these studies has 
the accuracy of detecting different genes been compared nor has the value of detecting 
multiple genes in combination been considered. 
Walter ct al. (1992) concludes that their study 'demonstrates the utility of EBV detection 
by the polymerase chain reaction in the evaluation of patients with metastases to neck 
nodes from occult prim.my carcinomas.' Pacchioni et al. (1994) in their study on 
undifferentiated NPC (UNPC) makes a similar conclusion that is 'detection of EBV in 
cervical metastatic adenopathy may be successfully used to identify the presence of 
occult UNPC.' MacDonald et al (1995) says their results 'demonstrate the utility of 
NPC-diagnostic EBV gene amplification in FNA samples of neck metastases and suggest 
that the presence of the EBV genome in FNA samples of neck nodes is predictive of the 
presence of NPC.' Moreover, F einmesser et al. (1992) adds that 'the presence of EBV in 
metastases from an occult primary tumor is predictive of the development of overt 
nasopbazyngeal carcinoma' · 
It is the objective of this study therefore to confirm the value of detecting EBV DNA as a 
diagnostic tool in NPC in this region Using a larger-sized sample, this study will also 
attempt to compare the accuracy of EBV DNA detection of three different genes, and its 
value when taken in combination Cl\apter 2 details the general and specific objectives of 
this study. In Chapter 3, the exact methodology of patient selection, specimen collection, 
stratification, laboratory analysis and statistical method is outlined In Chapter 4, the 
results of this study are presented together with its validity data and statistical 
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significance. Finally, in chapter 5, the importance and significance of the results are 
discussed and reCOIIImelldations are presented in Chapter 6. 
2 Objectives 
2.1 General objectives 
2.1.1 To evaluate the amplification of EBV DNA in tissue as a diagnostic tool for 
nasophruyngeal ·carcinoma 
2.1.2 To establish Malaysian data regarding the amplification of EBV DNA in ~ssue of 
nasopbatjngeal carcinoma ~ 
2.1.3 To -compare the detection rate of various EBV genes individually and in combinations, in 
the tissue of nasopharyngeal 'Carcinoma 
2.2 Specific objc~ves 
2.2.1 To establish the validity of EBV DNA detection of three EBV genes (EBNAl, EBNA2 
and LMP) in postnasal space biopsy and fine..needle aspirate of neck masses in NPC 
2.2.2 To determine the diagnostic accuracy of EBV DNA detection of three paired·gene 
-combinations in postnasal space biopsy and fine-needle ·aspirate of neck masses in ~TPC 
2.2. 3 To determine the optimal diagnostic cut-off value fur the total number of genes detected 
in postnasal space biopsy and fine-needle aspirate of neck masses in NPC 
2.2.4 To compare the accmacy of FNAC nnd PCR in the detection of metastatic nodal disease 
2.2.5 To ascertain the association between EBV genes with histological type 
3 Methodology 
This is a study to evaluate the validity of DNA amplification of various Epstein-Barr viral 
genes compared to histopathological examination (HPE) as the gold standard 
3.1 Population, period and place of study 
3.1.1 Population: Patients from the Otorhinolaryngology clinic of Hospital USM, Kelantan and 
Ear, Nose and Tiuoat Clinic of Hospital Pulau Pinang 
3.1.2 Period of study: July 2002 to September 2003 
3.1.3 Place of study: Otorhinolaryngology Clinic of Department of Otorhinolaryngology and 
Head & Neck Surgery, USM, Ear, Nose, and Throat Clinic of Hospital Pulau Pinang, 
Microbiology Laboratory of Department of Microbiology, Histopathology Laboratory of 
Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia (USM). 
3.1 Sample size 
3 .2.1 Active 
71 tissue specimens positive for nasopharyngeal carcinoma were selected for PCR 
analysis (36 primary twnour biopsy and 35 nodal metastasis fine-needle aspirates) from 
patients who fulfilled the inclusion criteria. These specimens were grouped as 
1. Group N {36) - proven NPC, postnasal biopsy of primary tumour in the nasopharytL"' 
2. Group F (35) - proven NPC, fine-needle aspirate of metastatic neck node 
3 .2.2 Control 
71 tissue specimens negative for nasopharyngeal carcinoma were· selected (36 postnasal 
space biopsy and 35 neck mass fine-needle aspirates) from patients who fulfil the 
inclusion and exclusion criteria 
These specimens were grouped as: 
1. Group A (36) -proven non-NPC, postnasal biopsy 
2. Group B (35)- proven non-NPC, neck mass fine-needle aspirate 
3.2.3 Sample size calculation 
Sample size was derived with a Power and Sample Size Program®t,_ based on the 
confidence limit of 0.95, type I error {a] of 0.05, power of study {1-j:l] of 0.9, type II 
error{~] of 0.1, odds ratio [\II] of 171, and correlation coefficient [~] (arbitrary) of 0.5. 
t Copyright © 1997 by William D. Dupont and Walton D. Plummer. 
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The· required sample· size- of 34 pairs for- each group was reached (34 for postn:lSal space 
biopsy and 34 for neck mass FNAC.) 
3.3 Patient recruitment 
Th~ number of patients recruited into this study was less than the number of specimens as 
more than one specimen may have been procured from a single subject Postnasal 
biopsy and fine-needle aspiration were performed in patients with a primary tmnour and 
neck metastasis. Fine-needle aspirates were taken from each neck node if multiple 
clinically suspicious neck nodes existed. 
3.3.1 Inclusion criteria 
o Patient with suspected nasopharyngeal carcinoma, with or without neck 
metastasis, Wldergoing postnasal space biopsy 
o Patient with neck mass undergoing fine-needle aspiration- confirmed 
cytologically or histopathologically to be a head and neck cancer other than the 
lymphomas, a benign disease or normal nodal tissue. 
3.3.2 Exclusion criteria 
o Patients with more than one head and neck malignancy, 
o Patients who have been subjected to radiotherapy or chemotherapy, or 
o Debilitated patients who are unable to tolerate biopsy, fine-needle aspiration or 
SlJTgety. 
3.3.3 Consent 
Informed consent was obtained before enrolling a patient into the study. He or she would 
be made to understand the nature of this study as explained in the Information Sheet 
(Appendices Band C) and must voluntarily agree to be part of this. research. A translator 
was provided and consent was taken in the presence of an impartial witness when the 
patient could not understand English or Malay. 
3.3.4 Proforma 
The patients' data were recorded in a Proforma (Appendix D) designed for this study. 
The data includes:-
o Patient biodata 
o Inclusion and exclusion criteria 
o Tissue collection- type and date 
o Tumour TNM staging 
o Histopathological type and grade-
a Laboratory analysis and results 
3.4 Specimen c:oUedion 
Tissue was taken pre-emptively during routine diagnostic biopsy of the nasopharYnx or 
fine-needle aspiration of neck masses. As the diagnosis was not known at the time of 
biopsy, tissue was stored and subsequently classified into the various groups (N, F, A, B) 
based on the histopathology report. Patients in the active groups (N and F) may have had 
one or more specimens taken as part of routine diagnostic investigations- a biopsy of the 
primary tumour of the nasopharynx and/or a fine-needle aspiration of the metasta~c neck · 
node for each clinically suspicious neck node present. Patients in the control groups (A, 
B) may have had one or more tissue specimens taken from them - either from the 
nasopharyn."" or from a palpable neck node of any pathology other than NPC or 
lymphoma 
3.4.1 Biopsy ofthe nasopharynx 
Informed consent was obtained and a biopsy from an obvious growth or the Fossa of 
RossenmUller under visualisation was performed with a rigid or flexible endoscope in the 
standard way (Fig. 8}. The main bulk of tissue was placed in fonnaldehydc to be sent for 
HPE and a small segment of tissue, 1-2mm in size was placed in a 1.5mL tube and stored 
for later analysis pending histopathological confirmation . If the histopathological 
examination (HPE) proved to be positive for NPC, the patient was recruited into the study 
under group N and if negative the specimen was used as a control in group A. 
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3.4.2 Fine-needle aspiration of neck masses 
Informed consent was taken for each patient and fine-needle aspiration was performed 
for neck masses using a 23G needle, 20cc syringe and needle biopsy carrier in the 
standard way (Fig. 9). The main bulk of aspirate was smeared onto slides for cytological 
examination and the remainder put into a 1.5mL tube and stored for later DNA analysis. 
If the specimen belongs to a patient with confirmed nasopharyngeal carcinoma on biopsy 
of the nasopharynx, it is classified under group F. Otherwise the specimen was classified 
under group B unless cytological examination shows lymphoma, in which case it is 
excluded (because certain lymphomas are known to contain EBV and can be diagnosed 
byFNAC alone) 1 
3.4.3 Storage and transport 
Tissue specimens in 1.5mL tubes were stored in a freezer at the clinic temporarily and 
then transported in an ice-box to the -200C freezer at the soonest possible time. 
3.5 Laboratory analysis 
3.5.1 Histopathological examination (HPE) 
All specimens collected were sent for routine histopathological and cytological 
examination. The diagnosis obtained from the pathologist confirmed nasopharyngeal 
carcinoma or otherwise and determined how they were classified (N,F ,A,B). PCR results 
were compared to the histopathological diagnosis as the gold standard. 
3.5.2 PCR Analysis 
All 138 tissue specimens with sufficient DNA (human J3-actin gene positive) from the 
active and control groups were subjected to PCR analysis. This method involves three 
main steps: 
1. Extraction of total DNA from tissue specimens, 
2. Amplification of total DNA by PCR, and 
3. Detection ofEBV DNA by agarose gel electrophoresis. 
PCR was performed at the Department of Microbiology, USM. They were analysed for 
the presence of three EBV genes - EBNA1, EBNA2 and LMP 1 - and the human ~-actin 
gene to ensure sufficient amounts of DNA extraction. 
3.5.2.1 Primer design 
3.5.2.2 
3.5.2.3 
Primers are short oligonucleotides made of T,A,G and C nucleotides used by DNA 
polymerase to initiate synthesis of new complementary strands of DNA Forward and 
reverse primers were designed for the Epstein-Barr virus genes EBNA1, EBNA2 and 
LMP and also for the human 13-actin gene (Table 2). 
Primers were custom-made according to specification by a commercial COII!pany 1 
(Appendix G). 
EBV DNA positive control 
EBV DNA positive control was derived from a B95-8 cell line2. EBV DNA from the 
B95-8 cell line was amplified with Taq polymerase PCR using primers designed 
specifically for EBNAI, EBNA2 and LMPI. The PCR products were then cloned into · 
PCR cloning vector TOPO 2.1 (Invitrogen) (Fig. 1 0). The positive clones were selected 
by PCR screening. The presence of EBV gene was further characterized by restriction 
analysis. The positive EBV clones were then used as positive control in each PCR 
analysis. 
Extraction of tissue DNA 
DNA from the tissue samples were extracted using the Nucleospin® tissue DNA 
extraction kit (Fig. 11) (Appendix G). Approximately 30mg of tissue was digested in 
lysis buffer containing Proteinase Kat 56°C overnight (Fig. 12, 13). The digested tissue 
sample was passed through a silica collmm (Fig. 14). Since DNA has a high affinity for 
silica, it binds to it, and pure DNA was eluted from the column using a low-salt buffer. 
1 Alpha DNA® 
2 Courtesy of Dr. Peh, University Malaya 
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3.5.2.4 Ainplillcatiun ofEBV DNA by PCR 
1) Forward ·and reverse primers' for EBNAl, EBNA2, and LMP genes of the 
Epstein-Barr virus were used in the polymerase chain reaction. Probes for the 
human -~-actin gene were also used for every set to -collJ..cnm sufficient quantity of 
DNA available for PCR amplification. 
3.5.2.5 Detection ofPCR product by electrophoresis 
The PCR product obtained was run on 1% agarose gel containing ethidium bromide at l G 
volts/em (Fig. 16, 17, 18). Electrophoresis separates DNA molecules based on size and 
charge in an electric field. Ag-aiose is a seaweed t.'lat, when boiled, fonns a lnatrix of 
·m.terlocking fibres and pon~s. The PCR product is loaded into wells at one end and 
negatively charged DNA migrates towards the anode. Smaller molecules will migrate at 
a higher velocity, resulting in a gradient based on molecular size. Ethidium bromide binds 
to DNA and serves as a DNA staining agent. Using an image analyser, DNA bands will 
fluoresce under ultraviolet light and an image is photographed using the image analyzer. 
The expected product sue is compared with a .l'lmrker·(Appendix G). 
3.6 Data collection 
All data were stored digitally using Microsoft Excel 2000 spreadsheet as a database. 
3. 7 Statistical analysis 
All statistical analyses were performed using the proprietary software MedCalc® ver 
7.2.0.2t. 
3.7.1 Specific Objective 1 : To establish the validity of EBV DNA detection of three EBV 
genes (EBNAI, EBNA2 and LMP) .in postnasal space biopsy and fine-needle aspirate of 
neck masses, in NPC 
3.7.2 Specific objective 2 : To determine the diagnostic accuracy of EBV DNA detection of 
three paired-gene combinations in postnasal space biopsy and fine-needle aspirAte of neck 
masses, in NPC 
The detection rate for three EBV gene-pairs for active and control groups were tabulated, 
ie. for 
o EBNAI & EBNA2 
o EBNAI & LMP1 
o EBNA2 & LMP1 
3.7.3 Specific objective 3: To determine the optimal diagnostic cut-off value for the total 
number of genes detected in postnasal space biopsy, in NPC. 
The detection rate for using different cut-off points total number of genes for active and 
control groups were ·tabulated, i.e. for 
o Cut-off point- 1 or more genes (>0) 
o Cut-off point- 2 or more genes (> 1) 
o Cut-off point- 3 genes {>2) 
3.7.4 ·specific tJbj·ective 4: To compare 1he accuracy of F.NAC and PCR in ·the detection of 
metastatic nodal disease 
The results of FNAC in clinically positive neck nodes of patients \\tit.'l proven pdmary . 
tumour ofNPC were compared with the detection ofEBV genes by percentages. · · 
3.7.5 Specific objective 5: To ascertain the association between EBV genes Wilh histological 
type. 
Detection rates for each gene were calculated for each histological type - Type I, II and 
m - according to the WHO classification 
4 Result 
4.1 Subjects 
4.1.1 Postnasal space biopsy 
In the period of study, tissue from a total of 86 postnasal space biopsies were collecled 
and stored. 
t Copyright© 1993-2003 Frank Schoonjans 
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Upon histopathological confirmation of the 86 postnasal biopsies, 36 were positive for 
nasopharyngeal carcinoma and 50 were negative (of which the first 36 were selected for 
PCR analysis). Dming PCR analysis for human 13-actin gene, one specimen from group 
N and one from group A was negative and du1y excluded from the study. The final 
number of specimens was for Group N - 35 specimens and Group A - 35 specimens. 
The breakdown of their histopathologica1/cytological diagnoses is as follows: 
o Group N (35) 
o WHO type I- 4 (11.4%) 
o WHO type n- 3 (8. 6%) 
o WHO type ill- 28 (80%) 
o Group A (35} 
o No malignancy- 32 (91.3%) 
o Chronic inflammation -3 {85. 7%) 
4.1.2 Fine-needle aspirate of neck masses · 
In the period of study, tissue from a total of 71 fine-needle aspirates were collected and 
stored. Upon cytological and histopathological confirmation, 36 neck nodes belonged to 
patients with nasopharyngeal carcinoma (proven by postnasal biopsy) and 35 others had 
other diagnoses. One specimen from group F was reported as a 'vascular tumor' and thus 
excluded on the grotmds that it may have been a second primary (as per exclusion 
criteria). Dwing PCR analysis for human ~-actin gene, one specimen from group F and 
one from group B were negative and duly excluded from the study. The final number of 
specimens was Group F - 34 specimens and Group B - 34 specimens. 
The breakdown of their cytological diagnoses is as follows: 
o Group F (34) 
o Metastatic carcinoma- 23 (67.6%) 
o No malignancy- 4 (11.8%) 
o No diagnostic material or insufficient for evaluation- 4 (11.8%) 
o Atypical cells- 2 (5.9%) 
o Necrotic debris -1 (2.9%) 
o Group B (34) 
o Metastatic CA (10)- from ethmoid CA (2), CA ovary (1), oral CA (3), 
Undifferentiated parotid CA (2) and unknown primacy (2) - (29.4%) 
o No malignancy- 3 (8.8%) 
o Chronic inflammation- 2 (5.9%) 
o Cystic lesion- 1 (2.9%) 
o Lymphoid cells - 1 (2.9%) 
o No diagnostic material or insufficient for evaluation- 17 (500/o) 
4.2 Individual EBV gene detection for postnasal space biopsy 
Table 2- Validity data for individual EBV gene detection in postnasal space biopsy 
(N series) 
EBNAI EBNA2 LMP1 
Sensitivity 97.14% 88.57% 91.43% 
Specificity 100.00% 94.29% 88.57% 
Positive predictive value 100.00% 93.94% 88.890/o 
Negative predictive value 97.22% 89.19% 91.18% 
Likelihood ratio infinity 15.50 8.00 
95% Confidence interval -0.96% to 1.43% -4.68% to 7.66% 
-6.25% to 7.92% 
x:.t 0.0000 0.1667 0.0000 
p value 1. 000 (>0. 05) 0.6831 (>0.05) 1.0000 (>0.05) 
Kappa statistic 0.971 0.829 0.800 
4.3 Individual EBV gene detection for neck mass rme-needle aspirate 
Table 3- Validity data for individual EBV gene detection in fine-needle aspirate of 
neck masses (F series) 
EBNAI EBNA2 LiviPl 
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Sensitivity 88.24% 85.29% 88.24% 
Specificity 97.06% 100.00% 94.12% 
Positive predictive value 96.77% 100.00% 93.75% 
Negative predictive value 89.19% 87.18% 88.89% 
Likelihood ratio 30.00 infinity 15.00 
95% Confidence interval -2.42% to 8.22% 0.70% to 8.70% -4.21% to 9.23% 
x2 1.5000 4.1667 0.5714 
pvalue 0.2207 (>0.05) 0.0412 (>0.05) 0.4497 (>0.05) 
Kappa statistic 0.853 0.853 ~. 0.824 
4.4 Paired gene detection in postnasal space biopsy 
Table 4- Validity data for three paired-gene combinations in postnasal space biopsy 
(N series) 
EBNA1 + EBNA2 EBNA1 +LMP1 EBNA2+LMPI 
Sensitivity 88.57% 91.43% 88.57% 
Specificity 100.00% 100.00% 94.29% 
Positive predictive value 100.00% 100.00% 93.94% 
Negative predictive value 89.74% 92.11% 89.19% 
Likelihood ratio infinity infinity 15.50 
95% Confidence interval -L12%to 5.71% -1.67% to 4.29% -4.68% to 7.66% 
xz 2.2500 1.3333 0.1667 
pvalue 0.1336 (>0.05) 0.2482 (>0.05) 0.6831 (>0.05) 
Kappa statistic 0.886 0.914 0.829 
4.5 Paired gene detection in neck mass fine-needle aspirate 
Table 5 - Validity data for ~ee paired-gene combinations in fine-needle aspirate of 
neck masses (F series) 
EBNA1 + EBNA2 EBNAI +LMP1 - EBNA2 + LMPI 
Sensitivity 79.41% 82.35% 82.35% 
Specificity 100.00% 97.06% 100.00% 
Positive predictive value 100.00% 96.55% 100.00% 
Negative predictive value 82.93% 84.62% 85.00% 
Likelihood ratio infinity 28.00 infinity 
95% Confidence interval 2.99% to 11.59% -0.61% to 11.11% 1.81%to 10.14% 
x2 6.1250 3.1250 5.1429 
p value 0.0133 (<0.05) 0.0771 (>0.05) 0.0233 (<0.05) 
Kappa statistic 0.794 0.794 0.824 
4.6 Cut-off value analysis for total number of genes detected in postnasal space biopsy 
' ~ Table 6- Validity data for total number of genes detected in postnasal space biopsy 
(N series) 
>0/3 >113 >2/3 
0 Sensitivity 97.14% 91.43% 88.57% 
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Specificity 88.57% 94.29% 100.00% 
Positive predictive value 89.47% 94.12% 100.00% 
Negative predictive value 96.88% 91.67% 89.74% 
Likelihood ratio 8.50 16.00 infinity 
95% Confidence interval -3.03% to 6.67% -4.94% to 6.22% -1.12% to 5.71% 
X2 0.8000 0.0000 2.2500 
pvalue 0.3711 (>0.05) 1.0000 (>0.05) 0.1336 {>0.05) 
Kappa statistic 0.771 0.857 0.886 
4. 7 Cut-off value analysis for total number of genes detected in fine-needle aspirate of 
neclt masses -
>0/3 >1/3 >2/3 
Sensitivity 97.06% 85.290A, 79.41% 
Specificity 94.12% 97.06% 100.00% 
Positive predictive value 94.29% 96.67% 100.00% 
Negative predictive value 96.97% 86.84% 82.93% 
Likelihood ratio 16.50 29.00 infinity 
95% Confidence interval -4.83% to 4.83% -1.58% to 9.66% 2.99% to 11.59% 
x2 0.2500 2.2857 6.1250 
p value 0.6171 (>0.05) 0.1306 (>0. 05) 0.0133 (<0.05) 
Kappa statistic 0.912 0.824 0.794 
• 
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Table 7- Sensitivity, specificity and area-under-curve for ROC in cut-off points for FNAC 
Criterion Sensitivity(95%Cl) Specificity(95%Cl) Area tmder curve 
>0/3 97.1 ( 84.6- 99.5) 94.1 ( 80.3- 99.1) 0.956 
> 1/3 85.3 ( 68.9- 95.0) 97.1 ( 84.6- 99.5) 0.912 ~ 
>2/3 79.4 ( 62.1- 91.3) 100.0 ( 89.6-100.0) 0.897 
4.8 Comparison of FNAC and PCR 
In 11 cases ofNPC with neck metastasis, PCR was able to detect EBV DNA wbije FNAC 
failed to detect malignancy. However in one case, FNAC showed metastatic carcinoma 
while PCR failed to detect any of the three genes. 
Table 8- Comparison of EBV gene detection and various cytological fmdings in the fine-
needle aspirates of neck nodes in patients with lmown nasopharyngeal carcinoma. 
FNAC for neck EBNAI EBNA2 LMP1 Any 1 out of 3 
nodes in NPC genes 
(n=34) 
Metastatic CA 20/23 (87.0%) 20/23 (87.0%) 19/23 (82.6%) 22/23 (95. 7%) 
67.6% (23) 
No malignancy (4) 3/4 (75%) 2/4 (50%) 4/4 (100%) 4/4 (100%) 
No diagnostic 4/4 (100%) 4/4 (100%) 4/4 (100%) 4/4 (100%) 
material or 
insufficient for 
evaluation ( 4) 
Atypical cells (2) 2/2 (100%) 2/2 (1000/o) 2/2 (100%) 2/2 (100%) 
Necrotic debris (1) III (100%) 111 (100%) Ill (100%) 1/1 (100%) 
Tota1_(34) 30/34 (88%) 29/34 {85.3%) 30/34 (88.2%) 33/34 {97.lo/~ 
4.9 Comparison of histological type and EBV gene detection by PCR 
Of the 35 specimens of NPC postnasal biopsy tissues, 4 were classified as WHO type I 
(keratinizing squamous cell carcinoma), 3 were WHO type IT (non-keratinising squamous 
cell carcinoma) and the other 28 were WHO type m (undifferentiated carcinoma). 
A comparison of the histological type and EBV gene detection by PCR is tabulated below. 
Table 9 - Comparison of histological type and EBV genes 
EBNAI EBNA2 LMPl 
WHO type I (4) 4/4 4/4 4/4 
WHOtypell (3) 3/3 3/3 3/3 
WHO typ_e m (28) 27/28 24/28 25/28 
12 
.. 
5 Discussion 
5.1 Significance of results 
35/36 positive nasopharyngeal biopsies and 35/36 negatives contained sufficient DNA 
EBNAl gene was detected in 34/35 positive specimens and in none of the controls. 
EBNA2 gene was detected in 31/35 positive specimens and in 2/35 controls. Ll\1P1 was 
detected in 32/35 positive specimens and in 4/35 controls. HPE failed to detect 
malignancy in one patient who had an obvious tumour of the nasopharynx but 'was only 
confinned to be NPC on a second biopsy 2 weeks later. EBV DNA was f01md in both 
specimens. . Another patient in the control group was positive for EBV DNA and 
developed NPC within 1 year. 
35/36 metastatic NPC specimens contained sufficient DNA and one was excluded due to 
presence of second primary. EBNAl gene was detected in 30/34 nodes and 1/34 
controls. EBNA2 gene was detected in 29/34 nodes and none of the controls. 
5.1.1 Individual EBV gene detection for postnasal space biopsy 
In the tissue obtained from postnasal space biopsy, detection of EBNA1 gene is 
considerably better than that of EBNA2 and LMPl, showing a high sensitivity (97.1 %) 
compared to EBNA2 (88.6%) or LMP1 (91.4%), and an extremely high specificity (100%) 
compared to EBNA2 (94.3%) or L:M.Pl (88.6%) as shown in Table 4. All three detection 
rates have p values above 0.05 on McNemar's test (Table 4)- i.e. there is no significant 
difference between PCR and HPE. This shows the EBV DNA detection to be on par with 
the gold standard of histopathological examination This is supported by the Kappa 
statistic which shows an excellent inter-test agreement (0.97) for EBNAI and good 
agreement (0.8-0.9) for the other two genes (Table 4). Comparing the ROC curves with 
one another, the results indicate that EBNAl gene has the highest area-under-curve (0.99) 
and is significantly different from that of LMP1 (p<O.OS), and no statistical difference is 
shown between EBNA2 and LMP1 (p>0.05) as shown in Table 5 and 6. EBNAI gene. 
showing the highest sensitivity and specificity. Kagpa value and area under the ROC 
curve. makes it the most suitable and specific gene for the diagnosis ofNPC in the biopsy 
tissue of the postnasal space. It is on par with the gold standard of HPE and can provide 
an adjunct or alternative to diagnosis when it is not forthcoming from histopathological 
examination. 
5.1.2 Individual gene detection for fine-needle aspirate of neck masses 
In this study, a clinico-pathological criteria (i.e. clinically suspicious neck nod~ with 
histopathologically-confirmed NPC of the primary site) is taken as evidence of neck 
metastasis. In the fine-needle aspirate of neck masses, detection of EBNAl and LMPl 
genes are equally sensitive (88.3%) while EBNA2 is only slightly lower (85.3%) as 
shown in Table 7. However EBNA2 stands out in specificity .(100%) while EBNAI 
comes in second (97.1%- 1 false positive) followed by LMP1 (94.1%- 2 false positives). 
All three detection rates have p values above 0.05 on McNemar's test (Table 4)- i,e. there 
is no significant difference between PCR and clinico-pathological criteria The Kappa 
statistic in this set is consistently high (>0. 8) for all three genes, with EBNAl and 
EBNA2 showing equal and the highest level (0.853) of inter-test agreement with 
histopathology (Table 7). Comparing their ROC curves with one another, the results 
indicate that the detection of EBNA1 has the highest area-under-curve (0.97) and is 
significantly different from that of EBNA2 and LM.Pl (p<0.05), but no statistical 
difference is shown between EBNA2 and LMPI (p>0.05) as shown in Table 8 and 9. 
EBNAI gene showing the highest sensitivity. Kappa value and area wder the ROC 
curve. makes it the most suitable single gene for the diagnosis of metastatic NPC in the 
fine-needle aspirate of neck masses, A slight compromise in specificity (97 .1 %) 
compared to EBNA2 (100%) should be acceptable. However. EBNAl gene detection 
(88.3% sensitivity) is superior to FNAC where the diagnostic accuracy is 67.6% in this 
study (Table 18l. It becomes vezy valuable in suggesting NPC as the origin of occult 
primaries and can guide the clinician in the diagnostic workup. 
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5. I. 3 Paired gene detection in postnasal space biopsy 
Taken in pairwise combinations (where two genes in a pair must both be detected to 
qualify as a ~positive'), the EBNAI-LMPI combination seems to show the best 
sensitivity (91.4%) and specificity (100%) compared to the other two combinations which 
have lower sensitivities (88.6%) and equal or lower specificity (EBNA1-EBNA2 :._ 100%, 
EBNA2-LMP1 - 94.3%) -as shown in Table 10. . All three pairwise combinations have 
p values above 0.05 on McNemar's test (i.e. no significant difference from the gold 
standard of histopathological exanrination) This indicates that pairwise-combinations are 
on par with the gold standard of HPE, supported by the Kappa statistic which shows that 
the EBNAl-LMPl has an excellent inter-test agreement (0.91) followed by the;J?BNA1-
EBNA2 combination (0.89) and EBNA2-LMPI combination (0.83)- as shown in Table 
10. The area-1.n1der-tbe-ROC-curve is best also for the EBNAl-LMPl combination (0.96) 
but comparing the ROC curves, all three pairwise combinations show no significant 
difference from each other. (p>O. 05) - as shown in Table 11 and 12. Therefore, the 
EBNAI-LMPI combination is the most suitable pairwise combination of genes for the 
diagnosis of NPC in postnasal mace biopsy. It is on par with HPE but not superior to the 
single gene detection of EBNAI. This can also be used as adjunct or alternative to 
diagnosis when it is not forthcoming from histopathological examination 
5 .1. 4 Paired gene detection in fine-needle aspirate of neck masses 
The paired combination of EBNA2-LMP1 combination (where two genes in a pair must 
both be detected to qualify as a ~positive') shows the best sensitivity (82.4%) and 
specificity (100%) compared to the other two combinations which have equal or lower 
sensitivity and equal or lower specificity (Table 13). However, only the EBNA1-LMP1 
combination shows a p value above 0.05 on McNemar's test (i.e. no significant difference 
from clinico-pathological criteria) The Kappa statistic is best for the EBNA2-LMP1 
with the highest inter-test agreement with histopathology (0.82) followed by the other two 
combinations (0. 79). The area-under-the-ROC-curve is best also for the EBNA2-LMPI 
combination (0.91) but comparing their ROC curves, all 1hree pairwise combinations 
show no significant difference with each other (p>0.05) as shown in Table 14 and 15. 
Therefore. while the EBNA2-LMP1 combination is the best of the three pairwise-
combinations it is not on par to the gold standard of histopathology and not superior to 
the single gene detection ofEBNAI. 
5.1. 5 Cut-off value analysis for total number of genes detected in postnasal space biopsy 
Analysis of the cut-off point shows a reciprocal relationship where the sensitivity 
decreases and specificity increases with increasing cut-off point from >0/3 to >2/3. The 
>0/3 cut-off point gives the best sensitivity (97.1%) and lowest specificity (88.5%) while 
the >2/3 cut-off point has the highest specificity (100%) and lowest sensitivity (88.6%)-
as shown in Table 16. All three cut-off points have p values above 0.05 on McNemar's 
test (i.e. no significant difference from HPE.) The >2/3 cut-off point has the highest 
value for Kappa statistic (0.89) and area-under-ROC-curve (0.94)- as shown in Table 17. 
However, comparing there area-under-ROC-curves, there is no significant difference 
between the three cut-off points with one another (p>O. 05). 
For a disease such as NPC it is desirable to use a cut-off ooint which offers the highest 
sensitivitv so as not to miss detecting a potentially curable disease (while a high 
specificity is desirable in a disease with grave prognosis.) Since there is no significant 
difference between the three cut-off points. it is arguably better to use the >0/3 ·or > 1/3 
cut-off points which offer better sensitivity (91.4-97.1%). It is on par. ·with 
histopathological detection but not superior to single gene detection ofEBNAI. 
5.1. 6 Cut-off value analysis for total number of genes detected in fine-needle aspirate of neck 
masses 
Analysis of the cut-off points in fine-needle aspirates show a similar reciprocal 
relationship between sensitivity and specificity. The >0/3 cut-off point gives the best 
sensitivity (97.1 %) and lowest specificity (94.1 %) while the >2/3 cut-off point has the 
highest specificity (100%) and lowest sensitivity (79.4%) -as shown in Table 18. All 
three cut-off points have p values above 0.05 on McNemar's test (i.e. no significant 
difference from clinico-pathological chteria). The >0/3 cut-off point has the highest 
value for Kappa statistic (0.91) and also for the area-under-ROC-curve (0.93) -as shown 
in Table 18 and 19. However, comparing their area-under-the-ROC-curves, there seems 
to be no significant difference between the three cut-o:ffpoints with one another (p>0.05). 
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Since >0/3 shows the best Kappa and area-under-ROC-curve values and offers the best 
sensitivity- which is ideal for a disease that is potentially curable- it is clearly the most 
suitable cut-off point in the diagnosis of metastatic NPC in fine-needle aspirate of neck 
masses. In fact. this is on par with HPE and superior to EBNAl single-gene detection 
and EBNA2-LMP1 paired gene detection This makes it ideal for the detection of 
metastatic NPC. especially in occult primaries. A summary table of the best detection 
methods for postnasal space biopsy and fine-needle aspirate of neck masses is presented 
in the table below. 
Table 10 - Comparison between single gene, paired gene and cut-off point for postni.sal 
space biopsy and fme-needle aspirate of neck masses. · 
Sensitivity Specificity Inter-test Area under p value 
agreement ROC curve (McNem.ar~s) 
(Kappa) 
N series - Postnasal space biopsy 
Single gene 97.1 100 0.97 0.99 >0.05 
EBNAl 
Paired gene 91.4 100 0.91 0.96 >0.05 
EBNA1-L.MP1 
Cut-off point 97.1 88.6 0.77 0.93 >0.05 
>0/3 
F series -Fine-needle aspirate of neck mass 
Single gene 88.3 97.1 0.85 0.93 >0.05 
EBNAI 
Paired gene 82.4 100 0.82 0.91 <0.05 
EBNA2-LMP1 
Cut-off point 97.1 94.1 0.91 0.96 >0.05 
>0/3 
In summary, for postnasal space biopsy tissue, single-gene detection using EBNAl is 
superior to paired-gene or cut-off point analysis in diagnosing NPC. One patient in this 
study was not known to be a case ofNPC at the time of biopsy but EBV DNA (EBNA2 
and L:MPI) was detected in the postnasal space biopsy tissue. In follow up, this patient 
subsequently developed NPC within 1 year of the test. This may be explained by the 
presence of EBV DNA in the preinvasive state as described by Patbmanathan et. al 
(1995) or NPIN m (Nasopharyngeal intra-epithelial neoplasia stage Ill) as described by 
Huang and Lo (1999). In another case, biopsy failed to detect malignancy in an obvious 
tumour but subsequently confirmed it in a repeat biopsy 2 weeks later. EBV DNA was 
found in both specimens. · 
One must conclude that the detection ofEBV genes is on par with HPE and that it can be 
an adhmct or alternative to diagnosis when the diagnosis is missed or when 
histopathological diagnosis is difficult for whatever reasons - e. g. non-representative 
biopsies submucosal disease. technical difficulties in intemretation <Allen. 1999). It can 
also predict the development of NPC and therefore alert the clinician to perfo~ serial 
biopsies and follow-yp a patient very closely rather than dismissing him/her as normal 
with fatal results. 
As for fine-needle aspirate of neck masses, a cut-off point of >0/3 is superior to either 
single-gene or paired-gene detection at the expense of a slight reduction in specificity 
compared to single-gene detection using EBNAI. In this study, a clinico-pathological 
criteria (i.e. clinically suspicious neck node in the presence of histopathologically 
confirmed NPC at the primary site) is taken as confirmatory of NPC. Barring open 
biopsy of a neck node, which worsens prognosis considerably (Cai et al., 1983), a clinico-
pathological criteria is the best means ~f diagnosing metastatic NPC. One must conclude 
that the detection of EBV genes in fine-needle aspirate tissue is on par with existing 
clinico-pathological criteria and by far superior to FNAC in detecting metastatic NPC. 
Therefore it is a valuable adjunct to guide the clinician in the diagnostic workup of occult 
primaries. 
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6 Conclussion 
6.1 
6.2 
6.3 
,· 
The final result of this study is presented according to their specific objectives, together 
with their validity data and statistical significance. These results have been obtained from 
an adequate sample size to achieve a power of study of 0.95. 
Individual EBV gene detection for postnasal space biopsy , 
The EBNAI gene is the best gene for detection of NPC in postnasal space t?ioJsy tissue 
and is statistically superior to EBNA2 and LMP1 genes. It has a sensitivity of 97.1 %, 
specificity of 100%, and inter-test agreement (Kappa) of 0.97 and is statistically on par 
with HPE as a diagnostic method. 
Individual gene detection for fine-needle aspirate of neck masses 
The EBNAl gene is the best gene for detection ofNPC in fine-needle aspirate tissue of 
neck masses and is statistically superior to EBNA2 and LMPl genes. It has a sensitivity 
of 88.3%, specificity of 97.1 %, an inter-test agreement (Kappa) of 0. 85 and is statistically 
on par with present clinico-pathological criteria and superior to FNAC as a diagnostic 
method. 
Paired gene detection in postnasal space biopsy 
The EBNA1-LMP1 pair is the best combination of 2 genes for the detection ofNPC in 
postnasal space biopsy tissue but it is not statistically superior to the other 2 pair-wise 
combinations. It has a sensitivity of91.4o/o, specificity of 100%, an inter-test agreement 
(Kappa) of 0.91, and is statistically on par with HPE as a diagnostic method 
6.4 Paired gene detection in rme-needle aspirate of neck masses 
The EBNA2-LMP1 combination shows the highest sensitivity (82.4%), specificity 
000%), and inter-test agreement (Kappa) of 0.82 but it is not statistically equal to 
clinicopathological criteria Therefore there is no valid pairwise combination for the 
detection ofNPC in fine-needle aspirate of neck masses. 
6.5 Cut-otT value for total number of genes detected in postnasal space biopsy 
A value of>0/3 is the best cut-off point to take in the detection ofNPC in postnasal space 
biopsy tissue as it offers the highest sensitivity (97 .1%) for detecting a potentially curable 
disease. At this cut-off point the specificity is 88.5% and inter-test agreement (Kappa) is 
0. 78, and it is statistically on par with HPE as a diagnostic method 
6.6 Cut-otT value for total number of genes detected in fine-needle aspirate of neck masses 
A value of >0/3 is the best cut-off point to take in the detection of NPC in fine-needle · 
aspirate of neck masses as it offers the highest sensitivity (97.1 %) for detecting a 
potentially curable disease. At this cut-off point the specificity is 94.1 %; inter-test 
agreement (Kappa) is 0.91, statistically on par with present clinico-pathological criteria 
and superior to FNAC as a diagnostic method 
6. 7 Presence of EBV DNA in histopathologically 'normal nasopharynx' 
The detection of EBV DNA is predictive of nasopharyngeal carcinoma even when 
histopathology is unable to detect malignancy in postnasal space biopsy tissue. 
6.8 EBV genes and histological type 
There is no significant ~ffer~ce. in the detection of EBV genes and histological type 
(according to WHO classification) m NPC . 
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In SUIIlillaJ)', EBV DNA detection in tissue obtained from postnasal biopsy and fine-
needle aspirate of neck masses is a relatively cheap, reliable and accurate method of 
diagnosing NPC, and 
1) It requires minimal ammmt of tissue and is rapid. . 
2) It is on par with histopathology in diagnosing NPC and on par with clinico-
pathological criteria in detecting metastatic NPC. 
3) It is superior to fine-needle cytology. 
4) It can serve as an adjunct when histopathological diagnosis is missed and can 
predict the development ofNPC. 
It . can . also suggest NPC and guide the clinician in the diagnostic workup pf occult 
prunanes. ·· 
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Conventional Biopsy to EBV Amplification Kit in ·Quick 
Diagnosis of Nasopharyngeal Carcinoma 
Shahid Hassan 
·Nasopharyngeal carcinoma (NPC) is the second most commonly occurring cancer amongst men after lung 
cancer in Malaysia. 1 The relative frequency in South East Asi~ and China is reported somewhere ¥ound 8% of all 
·malignancies in specialized clinics. It is a leading cancer in Southern China and Hong Kong, the highest concentration 
being 18% in certain racial areas of this part of the world. On the average the annual incidence in Hong Kong is 23.3 
per 100,000 population.2 
. Epstein Barr V~s (EBV) is associated with all types ~fNPC and the DNA of the virus is found in every cancer 
cell. EBV genomes consistently found in undifferentiated and well differentiated lesions have also been repo~ed 
in pre-invasive state of NPC.3 ·current·method of dia~osis i~ .J?;r~~iopsy of na_sopharynx and histopathological 
examuiation. Delay in diagnosis may be attributed to soxne misleading symptoms of, neck mass (43-55%), rhinologic 
(20-30%) and otologic (10-13%).4 Other factors include, late''piesentation occult-primaries (13.3%), false riegativ~ 
biopsies (submucosal disease) and low accuracy for FNAC. :Radiotherapy is the primary modality_oft~eatment and 
now 100% cure has been claimed in T1 No lesions. 
The ~onventiozial diagnostic method by nasopharyngeal biopsies arid fine needle aspiration of neck lumps 
have high rate offal~e negatives. Serological test for EBV antibody titre is also less helpful due to low sensitivity 
and specificity. EBV DNA in tumor cells detect~d by polymerase chain reaction ·(PCR) has been shoWn. to be mo:re 
-~ reliab~e and able to detect the c~cer before it develops clinically. The author and his team in University Sciences 
Malaysia has successfully conducted a study to evaluate the validity and reliability of detecting EBV genes in fuie 
. . 
needle aspirates and biopsy tissue in NPC by PCR. EBV products EBN~ and E:aN~ and LMP1 (generally 
i.nlplic~ted in ~neogenesis) t?gether with Beta-actin gene were analyzed With adequate sample in ~s study.for the 
first time in Southeast Asia. This ~as a f?tep forward towards the ultimate diagnosis ofNPC which otherwise may 
lead to an advance disease with regional metastasis adversely affecting the· prognosis due to .delay in diagn?~i~: 
· T~is ~c;l a few similar s~dies have given new hope towards the accurate diagnosis of NPC which has inperent . 
pitfalls in detection by. conventional methods based on histopathology. · 
. This.study has investigate~ the presence ofEBV DNA in the tissue obtained from primary nasopharynx and 
. the metastasis in the neck .. A randomized case control study recently conducted in University Sciences Malaysia by 
Author et al with highest ever sample size, utilizing polymerase chain reB:ctio~ method has shown the test 
. . . 
statistical.ly reljab.le With Kappa showing excellent inter-test ~greement of 9. 71 (HP~ the gold standard) and 
likelihood ratio of>15 with single EBNA1 gene det~ction. In two control subjects of the same study it 'Was est~blished 
that PCR analysis was helpful ~predicting the ~esion as NPC with an obvious lesion appearing later in 6 months. 
simiiarly unknown primaries in few cases with positl~e tissues on the needle as~irates fro:m occult ~e.ck metastasis,, 
by this method were also proven to be NPC. 
The outcome of this study suggests that EBV DNA detection is a highly sensitive and specific technique in 
diagnosmg metastatic NPC and therefore may be us~d to guide the diagnostic workup of occult primaries. This will 
necessitate a careful repeat bio.I?SY technique under direct ~sion from an anatomically occult area of nasopharynx. 
Further studies may be required to detect the rat? ofEBV DNA detection in other tumors like Hodgkin's, Bur kit's 
and B-celllymphoma and lympho-epithe~al carcinoma of salivary gland from the Head and Neck region. However 
rarity makes it difficult to obtain tissue and investigate the conditions associated with EBV. 
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Histopathology remains the gold standard for diagnosing NPC from the p~ary site, thou~h it is not without 
limitations as discussed above. EBV DNA detection can help when HPE fails to detect the malignancy. In clinically 
doubtful cases, the presence ofEBV DNA detection should raise the index of suspicions leading to a prompt repeat 
biopsy under general anaesthesia if necessary. 
In non-suspicious cases EBV DNA may indicate pre-invasive stage to be followed up closely with repeat biopsy 
every 03 months. In occult primaries in :Malaysian community, the presence ofEBV DNA will hugely suggest NPC 
if lymphoma has been ruled out by cytology as NPC is very common h~re. Especially in Chinese and Malay races 
one is almost certain that· occult primary with EBV DNA has odginated from the nasopharynx. 
Current Application- Developing a Diagnostic Kit: After the results obt.ained from this statistically significant 
. study with a large sample size which h.as proven the presence ofEBV DNA in NPC in Malaysia we c·a.n proceed to 
optimize this test. The v·ezy idea has helped us in cr~~t~~.~~.cliagnostic ki~ that i~ cheap an~ simple to use as 
compared to a PCR based test.which requires cold stor.~g~,'·~~agent transportation· and repeated freezing .and 
thawing giving rise to erroneous results. ·· · ·. 
To achieve EBV amplification (EBV Amp) diagn~stic kit, this test neede.d to be converted. to multiplex foz:m, 
i.e. all genes be ~plified at once in a single-tube and this is feasible as all4 genes have discretely different product 
size and can eas~y be discerned ~n eth~dium bromide stained electrophoresis gel. We have finally developed the 
EBV Amp Kit that contains thermostabilized PCR reagents in dry powder fo~ in 0.5ml tube and can ~e easily 
transported without an ice box. The test has been proven to be 97% se~sitive and 100% specific for EBV. The 
amplified product sizes are EBN~, EBN~, LMP1 and Beta-human actiD. gene .and~ internal control DNA 
extraction from tissue performed in standard way can be added t~ thermostabilized PCR mix tube and operated in 
PCR. machine to be finally analyzed on UV trans-illuminator. The result obtained is interpreted in a specified 
m:anner. The test in rapid and a result can be obtained in 3 hours after adding 20 micro litre of eXtracted DNA into 
the test tube containing PCR mastermix, fo~owed by polymerase chainre~ction (PCR) and. gel ~lectrophoresi~. 
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A · BREAKTHROUGH· IN NPC 
DIAGNOSIS ~FROM CONVENTIONAL BIOPSY 
TO EBV AMP KlT ~(The k i t won the g old medal 
best in venti ·on for 1- .Tex 2004) 
DR. SHAHID HASSAN, 
Department of ORL, School of Medical Sciences, Universiti Sains Malaysia Health Campus_ 
Nasopharyngeal carcinoma curable disease if detected early in 
(NPC) is the second highest cancer stage I or II ; however in the advance 
amongst men in Malaysia (Lung stage, five years survival rate 
Cancer being the first) . Epstein Barr drastically falls from 1 00-80% (in 
virus (EBV) is associated with all the stage I and II) to 58-38% (in stage 
types of NPC. In Peninsular Ill and IV). The diagnosis is 
Malaysia," the incidence of NPC is sometimes delayed with increasing 
365 cases per year or 5.4% of morbidity and mortality for non-
malignant tumors . of nasopharynx representative biopsy, submucosal 
(P rasad · arid . Rampal, 1992); disease an~ occult primaries. 
followed · by lymphomas, The conventional diagnostic 
adenocarcinomas and a_denoid method by nasopharyngeal biopsies · 
cystic carcinomas. It is potentially a and fine needle aspiration (FNA) of 
neck -lumps have high rate of false 
A D VISORS 
Profesor Zabldl Azhar Mohd.'Hussln 
Profesor Nor Hayatl Othman 
EDITOR 
profesor Mohd. Raza/1 Salleh 
negatives. EBV DNA in tumor cells 
detected by polymerase chain 
reaction (PCR) has been shown to 
be more rel.iabl~ and able to detect 
the cancer 
early before 
the -clinical 
maFJifestation. 
The author 
and his team 
in USM had 
successfully 
conducted a 
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study under IRPA short-tenii gra~t 
to evaluate the validity' and reliaMhy 
of detecting EBV genes in FNA and 
biopsy tissue of NPC ·by· ~CR. 
Adequate sample of EBV p·rodJc.ts 
EBNA1 and EBNA2 and LMP1r that 
are generally impl icatea ' ·5:rn 
oncogenesis, together with Beta-
actin were analyzed in this study 
conducted for the first timer•in 
Southea.st Asia-. This was a forWard 
step towards the ultimate diagnosis 
of prospective NPC, otherwise it 
may lead t o ari· advance disease 
with regional metastasis and 
adverse prognosis if diagnosed late. 
NPC is a unique cancer mos'tly 
presented with _huge"primary. and 
regional . metastasis, thus it 
d~mar:Jds qn early d.iagnosi_s to~ 
EDITORIAL BOARD IN THIS ISSUE 
Profesor Jafrl Malin Dato' Abdullah 
or. H}. Abdul Kareem 
or. Shahld Hassan 
TYPESETTING & LA YOUT 
MiJhamad·SaldtBin Hamzah 
Unit Pe!J.fJrbltan; Pusat Pengajlan Sa ins 
'perubatan, i). ~. M., Kampus Keslhatan, 
·1 e1sa,' i<ubanri kertiin, · Ketsntan. 
.. :· . . . ,; 
. ,1'. 
PRINTING 
Unit Parco taken, Pus at Pengajlan Sa ins 
Porubatan, U. S. M., Kampus Keslhatan, 
15180, Kubang Ker/an, Kelantan. 
· A Breakthrough in NPC 
Diagnosis ... I t 1, 3 
From The Editor ... 2 
Short Communication ... 4 
Departmental Research 
' 
·Activities ... 5 
. • .J ~ 
R & D Activities in 
PPSP ... 6- 10 . ·. 
Abstracts of Th'e . 
Selected Papers ... 11 - 13 
Research News 
Update .. . 13 - 15 
Research Personality: 
Assoc. Prof (Dr) ... .· '. 
Mustaffa Musa ... :. 16, ·15 
• ••4. :····,.··· •• ....... ··,:_ . ,.·! _., ... } · . :_ ,_. ··.·· ::~\-~. ~.. ,._, .. 
· . ·: :· . "'" . . · c·: 0 f./ 1'.1 W ~u .E. I> ·:· F:R O.M ·.· ·.1 , ~- ~ PA-GE. . ~- .' .--~l 
• o ' I 0 '•' • • • • ' ' ' '• ' 
0 
' - , ' • : • ' • o , • ' • " ' I ,.: 
with regional metastasis _and adverse prognosis if 
diagnosed late. NPC is a unique cancer mostly 
presented with huge primary and regional metastasis, 
thus it demands an early diagnosis for better prognosis. 
This and a few other similar studies have given new 
hope towards the accurate diagnosis of NPC which may 
have pitfalls in detection by conventional methods based 
on histopathology. 
Application of this Study Test in Clinical Practice 
This study investigated. the presence of EBV DNA in 
metastatic neck of unknown primaries, i.e. NPC. The 
outcome of this study suggests that EBV DNA detection 
is a highly sensitive and specific technique in diagnosing 
metastatic NPC and therefore may be used to guide 
the diagnosti c workup · of occult primaries. This will 
necessitate a careful repeat biopsy technique under 
Future Application- Developing a Diagnostic Kit 
After ob.taining the results frqm this statistically 
significant study with a large sample size which has 
proven the presence of EBV DNA in NPC, we can 
. 1( 
proceed to optimize this test. This will help us creating 
a diagnostic kit that is cheap and simple to use as 
compared to a PCR based test which requires cold 
storage, reagent transportation and repeated freezing 
and thawing that lead to erroneous results. 
Th create EBV amplification (EBV Amp) diagnostic 
kit, the test needs to be converted to multiplex form, i.e. 
all genes ?re simultaneously amplified in a single tube. 
This is feasible as all 4 ge~es have discretely different 
product size and can easily be discerned on ethidium 
bromide-stained electrophoresis gel. We have finally 
developed the EBV Amp Kit that contains thermo-
stabilized PCR reagents in dry powder form in 0.5ml 
direct v ision from an anatomical ly occult area of tube, which can be easily transported without cold chain. 
nasopharynx. Further studies may be required to detect 
the rate of EBV DNA detection in other tumors like 
Hodgkin's, Burkih's and B-cell lymphoma and lympho-
epithelial carcinoma of salivary gland from the Head 
and Neck region which are rarely seen in Malaysia. 
However the scarcity of such cases makes it difficult to 
obtain tissue and investigate the conditions associated 
with EBV. 
Histopathology remains the gold standard for 
diagnosis of NPC in the primary site, though it is not 
without limitations as discussed above. EBV DNA 
detection is especially useful when HPE fails to detect 
The test has been proven to be 97% sensitive and 1 00% 
specific for EBV. The amplified product sizes are 
EBNA 1, EBNA2, LMP1 and Beta human actin gene, 
(lnd an internal control. DNA extraction from tissue 
performed in standard way can be added to thermo-
stabil ized PCR mix tube and operated in PCR machine 
to be finally analyzed on UV trans-illuminator. The result 
obtained is interpreted in a specified manner. It is hoped 
that this single tube DNA test for rapid Epstein-Barr virus 
detection will prove a breakthrough in early diagnosis 
of NPC which is mandatory for:·a:·possible cure. After 
being patented (in process) EBV Amp ki~ will be available 
the malignancy. In clinically doubtful cases, the detection for general use in NPC practice at reasonable price 
of EBV DNA should raise the index of suspicions leading together with detail of procedure, analysis of PCR · 
to a prompt repeat of biopsy under GA if necessary. In product, interpretation criteria and precaution to be taken 
. non-suspicious cases EBV DNA may indicate pre- while performing the test. 
invasive stage to be followed up closely with repeat' ' 
biopsy every ·3 months. In Malaysia, the presence of Acknowledgements 
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